Circular-L Tablet
By Circular-L
Rx
10 Tablet in a Strip

Composition
Levocetirizine(5mg) + Montelukast(10mg)

Manufacturer - Tri Mitsu Pharmaceuticals
Shop no. 07, 08 & 09, 1st floor, Shukan Complex, Opp. Bank of Baroda, New Ranip, Ahmedabad-382470, Gujarat, India

Expires on or after
September, 2025

liver
When using Circular-L Tablet, it is important to use caution if you have severe liver disease. Your doctor may need to adjust the dosage of the medication in such cases. It is advisable to consult with your healthcare provider before starting or changing the dosage of Circular-L Tablet if you have severe liver issues. There is limited information available regarding the use of this medication in patients with severe liver disease. However, no dose adjustment is typically needed for individuals with mild to moderate liver disease. It is essential to follow your doctor's guidance closely to ensure the safe and effective use of Circular-L Tablet.

kidney
Caution should be taken when using Circular-L Tablet in patients with kidney disease. Dose adjustment may be necessary. Avoid use in severe kidney disease. Consult your doctor for guidance.

alcohol
When taking Circular-L Tablet, it is important to be cautious when consuming alcohol. It is advised to consult your doctor regarding alcohol consumption while on this medication.

driving
When taking Circular-L Tablet, be cautious as it may reduce alertness, cause vision changes, or induce drowsiness and dizziness. Avoid driving if experiencing these effects.

pregnancy
During pregnancy, it is generally believed that Circular-L Tablet is safe to use as it has shown minimal adverse effects in animal studies. However, there is limited research on its effects in humans.

breastfeeding
Circular-L Tablet is not recommended for use during breastfeeding as it may be toxic to the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | RESPIRATORY |
Action Class | - |
₹135
Inclusive of all taxes
Content verified by

Dr. Archana Prabhakar
MBBS, M.Med (Family Medicine)
Last update on 18-Nov-2024